Quarter Period Consolidated Statement Of Income

STELLA PHARMA CORPORATION - Filing #7248023

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Quarter period consolidated statement of income
Statement of income
Net sales
961,058,000 JPY
269,491,000 JPY
Gross profit (loss)
845,748,000 JPY
217,298,000 JPY
Selling, general and administrative expenses
Depreciation
17,025,000 JPY
13,613,000 JPY
Selling, general and administrative expenses
935,995,000 JPY
977,598,000 JPY
Operating profit (loss)
-90,246,000 JPY
-760,300,000 JPY
Non-operating income
Interest income
598,000 JPY
11,000 JPY
Non-operating income
11,648,000 JPY
4,624,000 JPY
Non-operating expenses
Interest expenses
4,082,000 JPY
2,084,000 JPY
Non-operating expenses
59,271,000 JPY
4,533,000 JPY
Ordinary profit (loss)
-137,869,000 JPY
-760,208,000 JPY
Extraordinary losses
Extraordinary losses
JPY
768,000 JPY
Profit (loss) before income taxes
-137,869,000 JPY
-760,976,000 JPY
Income taxes - current
2,941,000 JPY
2,772,000 JPY
Income taxes
2,941,000 JPY
2,772,000 JPY
Profit (loss)
-140,811,000 JPY
-140,811,000 JPY
-140,811,000 JPY
-140,811,000 JPY
-763,749,000 JPY
-763,749,000 JPY
-763,749,000 JPY
-763,749,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.